WO2020080871A3 - Biomarker composition for determining cancer drug responsiveness, method for determining cancer drug responsiveness using biomarker composition, and diagnostic chip for detecting biomarker composition for determining cancer drug responsiveness - Google Patents

Biomarker composition for determining cancer drug responsiveness, method for determining cancer drug responsiveness using biomarker composition, and diagnostic chip for detecting biomarker composition for determining cancer drug responsiveness Download PDF

Info

Publication number
WO2020080871A3
WO2020080871A3 PCT/KR2019/013717 KR2019013717W WO2020080871A3 WO 2020080871 A3 WO2020080871 A3 WO 2020080871A3 KR 2019013717 W KR2019013717 W KR 2019013717W WO 2020080871 A3 WO2020080871 A3 WO 2020080871A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer drug
biomarker composition
responsiveness
determining cancer
drug responsiveness
Prior art date
Application number
PCT/KR2019/013717
Other languages
French (fr)
Korean (ko)
Other versions
WO2020080871A2 (en
WO2020080871A9 (en
Inventor
정종선
이선호
홍종희
Original Assignee
(주)신테카바이오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020190096410A external-priority patent/KR20200044677A/en
Application filed by (주)신테카바이오 filed Critical (주)신테카바이오
Publication of WO2020080871A2 publication Critical patent/WO2020080871A2/en
Publication of WO2020080871A3 publication Critical patent/WO2020080871A3/en
Publication of WO2020080871A9 publication Critical patent/WO2020080871A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to a biomarker composition for determining the responsiveness of a discovered cancer drug by using genetic biomarker labeling scan (GBLscan), which is a drug indication and responsiveness prediction system and method, as a new learning model capable of reliably predicting the responsiveness of a drug by performing coupling analysis on a molecular profile of the drug after transforming specific genetic variation fingerprints related to diseases including cancer into a haplotype having functional information, a method for determining cancer drug responsiveness using the biomarker composition, and a diagnostic chip for detecting a biomarker composition for determining cancer drug responsiveness.
PCT/KR2019/013717 2018-10-18 2019-10-18 Biomarker composition for determining cancer drug responsiveness, method for determining cancer drug responsiveness using biomarker composition, and diagnostic chip for detecting biomarker composition for determining cancer drug responsiveness WO2020080871A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
KR10-2018-0124512 2018-10-18
KR20180124512 2018-10-18
KR10-2019-0096410 2019-08-07
KR1020190096410A KR20200044677A (en) 2018-10-18 2019-08-07 Bio-Marker for Prediction of Drug Sensitivity, Estimation Method for Prediction of Drug Sensitivity and Diagnosing Chip for Prediction of Drug Sensitivity
KR1020190098165A KR20200054058A (en) 2018-10-18 2019-08-12 Bio-Marker Composition for Prediction of Drug Sensitivity, Estimation Method for Prediction of Drug Sensitivity using Bio-Marker Composition and Diagnosing Chip for Detection of Bio-Marker Composition for Prediction of Drug Sensitivity
KR10-2019-0098165 2019-08-12
KR10-2019-0098492 2019-08-13
KR1020190098492A KR20200054059A (en) 2018-10-18 2019-08-13 Bio-Marker Composition for Prediction of Drug Sensitivity, Estimation Method for Prediction of Drug Sensitivity using Bio-Marker Composition and Diagnosing Chip for Detection of Bio-Marker Composition for Prediction of Drug Sensitivity

Publications (3)

Publication Number Publication Date
WO2020080871A2 WO2020080871A2 (en) 2020-04-23
WO2020080871A3 true WO2020080871A3 (en) 2020-08-06
WO2020080871A9 WO2020080871A9 (en) 2020-09-24

Family

ID=70283510

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/013717 WO2020080871A2 (en) 2018-10-18 2019-10-18 Biomarker composition for determining cancer drug responsiveness, method for determining cancer drug responsiveness using biomarker composition, and diagnostic chip for detecting biomarker composition for determining cancer drug responsiveness

Country Status (1)

Country Link
WO (1) WO2020080871A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113652486B (en) * 2021-09-13 2023-02-03 新疆医科大学第四附属医院 Colorectal cancer treatment prognosis biomarker and application thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070031894A (en) * 2004-03-31 2007-03-20 더 제너럴 하스피탈 코포레이션 Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
US20080131885A1 (en) * 2006-03-31 2008-06-05 Memorial Sloan Kettering Cancer Center Biomarkers for cancer treatment
US20090298701A1 (en) * 2008-05-14 2009-12-03 Baker Joffre B Predictors of patient response to treatment with egf receptor inhibitors
US20100240665A1 (en) * 2008-10-20 2010-09-23 The Regents Of The University Of Colorado Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2669682A1 (en) * 2012-05-31 2013-12-04 Heinrich-Heine-Universität Düsseldorf Novel prognostic and predictive biomarkers (tumor markers) for human breast cancer
US20160024589A1 (en) * 2013-03-15 2016-01-28 The Broad Institute, Inc. Methods of identifying responses to map kinase inhibition therapy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070031894A (en) * 2004-03-31 2007-03-20 더 제너럴 하스피탈 코포레이션 Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
US20080131885A1 (en) * 2006-03-31 2008-06-05 Memorial Sloan Kettering Cancer Center Biomarkers for cancer treatment
US20090298701A1 (en) * 2008-05-14 2009-12-03 Baker Joffre B Predictors of patient response to treatment with egf receptor inhibitors
US20100240665A1 (en) * 2008-10-20 2010-09-23 The Regents Of The University Of Colorado Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2669682A1 (en) * 2012-05-31 2013-12-04 Heinrich-Heine-Universität Düsseldorf Novel prognostic and predictive biomarkers (tumor markers) for human breast cancer
US20160024589A1 (en) * 2013-03-15 2016-01-28 The Broad Institute, Inc. Methods of identifying responses to map kinase inhibition therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Table of Pharmacogenomic Biomarkers in Drug Labeling", WWW.FDA.GOV, June 2018 (2018-06-01), XP055727919, Retrieved from the Internet <URL:https://www.fda.gov/media/107901/download> *
BIGNUCOLO, A.: "Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 18, no. 7, 14 July 2017 (2017-07-14), pages 1522, DOI: 10.3390/ijms18071522 *

Also Published As

Publication number Publication date
WO2020080871A2 (en) 2020-04-23
WO2020080871A9 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
BR112018015913A2 (en) method for determining a copy number variation of a nucleic acid sequence of interest; and a system for assessing the copy number of a nucleic acid sequence of interest.
WO2007117444A3 (en) Protein detection by aptamers
GB2568608A (en) Personalized genetic testing
WO2007103541A3 (en) Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
MX2015016047A (en) Method and system for maintaining or improving wellness.
NZ630091A (en) Immunofluorescence and fluorescent-based nucleic acid analysis on a single sample
WO2012015765A3 (en) Method for using gene expression to determine prognosis of prostate cancer
WO2010148141A3 (en) Apparatus and method for speech analysis
BR112018015698A2 (en) ? diagnostic and prognostic methods for cardiovascular disease and events?
EA200802242A1 (en) METHOD FOR DETERMINING THAT, WILL BE OR WILL NOT BE A PATIENT BY RESPONDER FOR IMMUNOTHERAPY
WO2012125807A3 (en) Systems and compositions for diagnosing barrett&#39;s esophagus and methods of using the same
WO2010033371A3 (en) Molecular markers for lung and colorectal carcinomas
BRPI1008957B8 (en) method for simultaneous detection of a plurality of target nucleic acids performed by an integrated real-time target nucleic acid analysis system
WO2012122236A3 (en) Method and system to detect and diagnose alzheimer&#39;s disease
WO2009026381A3 (en) Method, computer program product and system for individual assessment of alcohol sensitivity
BR112013021056A2 (en) monoclonal antibody, hybridoma cell line, diagnostic kit, methods for producing a monoclonal antibody and binding agent, purified amino acid sequence binding agent, method for obtaining a coding nucleic acid sequence, antibody molecule encoding isolated nucleic acid, vector, isolated host cell, fusion protein, screening method for the presence of a disease, a condition, methods of diagnosing an individual, prognosis for an individual, and monitoring an individual, and , method for detecting the presence or absence of cervical cancer
WO2008128043A3 (en) Diagnostic and prognostic methods for renal cell carcinoma
BR112016019740A2 (en) inflammation state monitoring
WO2019055661A8 (en) Preeclampsia biomarkers and related systems and methods
WO2020080871A3 (en) Biomarker composition for determining cancer drug responsiveness, method for determining cancer drug responsiveness using biomarker composition, and diagnostic chip for detecting biomarker composition for determining cancer drug responsiveness
ATE492815T1 (en) DIAGNOSTIC BIOMOLECULE(S)
WO2012103260A3 (en) High-throughput methods to produce, validate and characterize mmabs
WO2008081203A3 (en) Fluorescence labelling
ATE468535T1 (en) USE OF NNMT AS A MARKER FOR LUNG CANCER
DE602005013430D1 (en) USING ASC AS A MARKER FOR COLORECTAL CARCINOMAS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19874536

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19874536

Country of ref document: EP

Kind code of ref document: A2